从口服抗凝剂的共同决策中吸取的经验教训:口服化疗决策辅助剂开发建议的观点
Daniel E McLoughlin1, Fabiola M Moreno Echevarria1, Sherif M Badawy1,2
1Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
开发用于口腔化疗的有效决策辅助工具 (DA) 对共享决策 (SDM) 至关重要. 来自抗凝血和瘤学DA的证据,以及患者的偏好,可以指导为口服化疗治疗选择创建以患者为中心的工具.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 患者决策辅助工具 患者决策辅助工具
背景情况:
- 口服化疗经常被处方,需要共享决策 (SDM) 以使治疗与患者价值观保持一致.
- 现有的决策辅助工具 (DA) 缺乏针对口服化疗独特挑战的具体证据.
- 需要基于证据的DA来支持SDM在口服化疗选择中.
研究的目的:
- 审查口服抗凝药和瘤学,以及患者偏好调查的DA.
- 为指导专门用于口服化疗的DA的开发.
- 确定创建有效患者决策支持工具的最佳实践.
主要方法:
- 对口服抗凝药和瘤学中DA的30篇同行评审出版物的系统综述.
- 对SDM原则,DA疗效和患者经验的分析.
- 综合患者偏好数据,以获得最佳的DA含量和输送.
主要成果:
- 在口服抗凝药中有效的DA提高了知识,减少了冲突,增加了坚持.
- 瘤学DA提高了患者的知识和价值调整的决策;无效的不清楚或过于乐观.
- 患者更喜欢DA详细说明好坏,副作用,问题和对生活质量的影响.
结论:
- 用于口服化疗的以患者为中心的DA应纳入患者的偏好,并让患者参与开发.
- 在任命之前提供DA和解决有效性障碍是关键考虑因素.
- 从口服抗凝药,瘤学和偏好调查中获取数据对于优化口服化疗DA至关重要.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
05:35Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Ethical Dilemmas II
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
